The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

Under the agreement, Singapore-headquartered ImmunoScape will develop what it calls a "Seed-and-Boost" immunotherapy, combining its T-cell receptor therapies (the "seed") followed by Cue's IL-2-based ...

DMT in recent months has focused resources on developing its lead gene therapy candidate 4D-150 in wet age-related macular degeneration.